Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 7
Submit an article Journal homepage
499
Views
13
CrossRef citations to date
0
Altmetric
Research Articles

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

Nicole Wong DooPeter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaCorrespondence[email protected]
,
Philip A. ThompsonRoyal Melbourne Hospital, Parkville, Victoria, Australia
,
H. Miles PrincePeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
,
John F. SeymourPeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
,
David RitchiePeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
,
Kerrie StokesPeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
,
Kate BurburyPeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
,
Max WolfPeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
,
Trish JoycePeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
&
Simon J. HarrisonPeter MacCallum Cancer Centre, East Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
 show all
Pages 1465-1472 | Received 24 Jul 2012, Accepted 31 Oct 2012, Published online: 14 Dec 2012

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Margarita Blanes, José D. González, Juan J. Lahuerta, Paz Ribas, Ignacio Lorenzo, Blanca Boluda, Miguel A. Sanz & Javier de la Rubia. (2015) Bortezomib-based induction therapy followed by intravenous busulfan–melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. Leukemia & Lymphoma 56:2, pages 415-419.
Read now

Articles from other publishers (12)

Alina Striha, A. John Ashcroft, Anna Hockaday, David A. Cairns, Karen Boardman, Gwen Jacques, Cathy Williams, John A. Snowden, Mamta Garg, Jamie Cavenagh, Kwee Yong, Mark T. Drayson, Roger Owen, Mark Cook & Gordon Cook. (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials 19:1.
Crossref
Eda Aypar, Fikret Vehbi İzzettin, Şahika Zeynep Akı, Mesut Sancar, Zeynep Arzu Yeğin & Gülsan Türköz-Sucak. (2017) Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. Journal of Oncology Pharmacy Practice 24:4, pages 281-289.
Crossref
Tomer M. Mark, Danielle Guarneri, Peter Forsberg, Adriana Rossi, Roger Pearse, Arthur Perry, Karen Pekle, Linda Tegnestam, June Greenberg, Tsiporah Shore, Usama Gergis, Sebastian Mayer, Koen Van Besien, Scott Ely, David Jayabalan, Daniel Sherbenou, Morton Coleman & Ruben Niesvizky. (2017) A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation 23:6, pages 930-937.
Crossref
E J Norris, D DeStephanis, B Tunquist, S Usmani, R Ganapathi & M Ganapathi. (2016) Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells. Blood Cancer Journal 6:10, pages e480-e480.
Crossref
Tulio E. Rodriguez, Parameswaran Hari, Patrick J. Stiff, Scott E. Smith, Danielle Sterrenberg & David H. Vesole. (2016) Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation 22:8, pages 1391-1396.
Crossref
N Shah, P F Thall, P S Fox, Q Bashir, J J Shah, S Parmar, P Lin, P Kebriaei, Y Nieto, U R Popat, C M Hosing, A Cornelison, E J Shpall, R Z Orlowski, R E Champlin & M H Qazilbash. (2015) Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29:9, pages 1945-1948.
Crossref
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach & Philip L. McCarthy. (2015) Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation 21:5, pages 793-798.
Crossref
Sascha A. Tuchman, Amy Lane, Whitney E. Hornsby, Caroline Bishop, Samantha Thomas, James E. HerndonIIII, Gwynn Long, Cristina Gasparetto & Lee W. Jones. (2015) Quantitative Measures of Physical Functioning After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Feasibility Study. Clinical Lymphoma Myeloma and Leukemia 15:2, pages 103-109.
Crossref
Sarah A. Holstein, Hong Liu & Philip L. McCarthy. (2014) Multiple Myeloma. Hematology/Oncology Clinics of North America 28:6, pages 1113-1129.
Crossref
Heinz LudwigPieter SonneveldFaith DaviesJoan BladéMario BoccadoroMichele CavoGareth MorganJavier de la RubiaMichel DelforgeMeletios DimopoulosHermann EinseleThierry FaconHartmut GoldschmidtPhilippe MoreauHareth NahiTorben PlesnerJesús San-MiguelRoman HajekPia Sondergeld & Antonio Palumbo. (2014) European Perspective on Multiple Myeloma Treatment Strategies in 2014. The Oncologist 19:8, pages 829-844.
Crossref
Makoto Nakamura & Kazutaka Sunami. (2014) Autologous stem cell transplantation for multiple myeloma. Journal of Hematopoietic Cell Transplantation 3:3, pages 64-78.
Crossref
Toshihiro Miyamoto, Goichi Yoshimoto, Tomohiko Kamimura, Tsuyoshi Muta, Shuichiro Takashima, Yoshikiyo Ito, Motoaki Shiratsuchi, Ilseung Choi, Koji Kato, Katsuto Takenaka, Hiromi Iwasaki, Yasushi Takamatsu, Takanori Teshima & Koichi Akashi. (2013) Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. International Journal of Hematology 98:3, pages 337-345.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.